Endocrinology (all articles)
RCT: The combination of liraglutide + exercise improves weight loss maintenance more than either treatment alone.
6 May, 2021 | 08:52h | UTCCommentary: Liraglutide beneficial for post-diet weight loss maintenance – Medwire News
Consensus Statement: Post-exercise recovery for the endurance athlete with type 1 diabetes.
6 May, 2021 | 08:42h | UTCPost-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Post-exercise recovery for the #endurance #athlete with type 1 #diabetes: a consensus statement https://t.co/eCmIeXtGDh #exercise #T1D #FREE to read with registration (also FREE)
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) April 17, 2021
USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)
5 May, 2021 | 08:30h | UTCDraft Evidence Review: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer
Study with 6.9 million people in England shows severe Covid-19 in young people can mostly be explained by obesity – At a BMI of more than 23 kg/m2, there was a linear increase in risk of severe COVID-19
30 Apr, 2021 | 08:22h | UTCCommentaries: Severe COVID in young people can mostly be explained by obesity – new study – The Conversation AND Obesity studies highlight severe COVID outcomes, even in young adults – CIDRAP AND Expert reaction to study looking at a potential link between body weight and risk of severe COVID-19, especially for younger adults – Science Media Centre
Commentary on Twitter (thread – click for more)
NEW—Study of health records of nearly 7 million people in England found that the risk of worse outcomes from #COVID19 starts rising in people with a BMI above 23kg/m2—considered to be in the healthy range.
Read in @TheLancetEndo: https://t.co/5ibn3yb1xO 1/2 pic.twitter.com/4MwnGq95Sz
— The Lancet (@TheLancet) April 29, 2021
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
Review: Non-alcoholic fatty liver disease
29 Apr, 2021 | 08:30h | UTCNon-alcoholic fatty liver disease – The Lancet (free for a limited period)
RCT: Metformin vs. insulin in gestational diabetes – metformin was associated better glycemic control, lower risk of hypoglycemia, and less maternal weight gain
25 Apr, 2021 | 21:03h | UTCMeDiGes Study. Metformin versus insulin in gestational diabetes: Glycemic control, and obstetrical and perinatal outcomes. Randomized prospective trial. – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
Related: Randomized trial tests metformin in women with type 2 diabetes in pregnancy AND Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis – PLOS Medicine AND Case-Control Study: Metformin Exposure in First Trimester of Pregnancy is Not Associated with Congenital Anomalies
AHA Scientific Statement: Obesity and Cardiovascular Disease
23 Apr, 2021 | 08:22h | UTCNews Release: More belly weight increases danger of heart disease even if BMI does not indicate obesity – American Heart Association
Survey: Despite guideline recommendations, many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone
23 Apr, 2021 | 08:13h | UTCTSH Suppression for Papillary Thyroid Cancer: A Physician Survey Study – Thyroid (link to abstract – $ for full-text)
Commentary on Twitter
Hot off the press. We found that many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone, emphasizing the need for more research to better guide thyroid cancer management. @AmThyroidAssn @UMRogelCancer https://t.co/iU3ObzQxBQ
— Maria Papaleontiou, MD (@MariaPapaleont1) March 30, 2021
AGA recommends intragastric balloons as an additional weight loss option for obese patients
23 Apr, 2021 | 08:10h | UTCOriginal article: AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity – Gastroenterology
Study: Postprandial glycemic dips predict appetite and energy intake in healthy individuals
21 Apr, 2021 | 06:36h | UTCCommentaries: New research reveals why some of us are hungry all the time – King’s College London AND The easy test that predicts the size of your next few meals – Nature AND Feeling Hungry All The Time? Scientists Have a New Explanation For What’s Going On – Science Alert
Commentary on Twitter
https://twitter.com/nresearchnews/status/1382354527572070401
M-A: Portal venous system thrombosis after bariatric surgery
21 Apr, 2021 | 06:16h | UTCPortal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis – Surgery (link to abstract – $ for full-text)
Podcast: Management of Obesity Hypoventilation Syndrome
20 Apr, 2021 | 05:23h | UTC#269 Obesity Hypoventilation Syndrome (OHS) and the Didgeridoo with Dr Aneesa Das – The Curbsiders
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
18 Apr, 2021 | 21:24h | UTC
Commentary on Twitter
Check out the latest @SCC_CCS Guideline for the Management of Dyslipidemia for the Prevention of #Cardiovascular Disease!! https://t.co/ZKC7DrMIOq #HotOffThePress @ThanassoulisMD @ArdenBarry @DrNatDayan @RuthMcPherson12 @HeartDocRx @SCC_CCS_KT @SCC_CCS_CEO @SCC_CCS_Trainee pic.twitter.com/LZFbXNjztP
— CJC Journals (@CJCJournals) March 27, 2021
Study: Teprotumumab for patients with active thyroid eye disease
20 Apr, 2021 | 05:25h | UTCTeprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Review: Endocrine complications of immunotherapies
15 Apr, 2021 | 06:13h | UTCEndocrine complications of immunotherapies: a review – Clinical Medicine Journal
WHO Calls For Expanding Access To Insulin At Launch of Global Diabetes Compact
15 Apr, 2021 | 06:25h | UTCWHO Calls For Expanding Access To Insulin At Launch of Global Diabetes Compact – Health Policy Watch
News release: New WHO Global Compact to speed up action to tackle diabetes – World Health Organization
Guidance: WHO global diabetes compact – World Health Organization
USPSTF Statement: Insufficient evidence to recommend Vitamin D deficiency screening
14 Apr, 2021 | 01:47h | UTCVitamin D Deficiency in Adults: Screening – U.S. Preventive Services Task Force
Evidence Report: Screening for Vitamin D Deficiency in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Editorial: The USPSTF 2021 Recommendations on Screening for Asymptomatic Vitamin D Deficiency in Adults: The Challenge for Clinicians Continues – JAMA AND Why USPSTF Still Finds Insufficient Evidence to Support Screening for Vitamin D Deficiency – JAMA Network Open
JAMA Patient Page: Screening for Vitamin D Deficiency in Adults
RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
9 Apr, 2021 | 03:18h | UTCAuthor Interview: Effect of High-Frequency (10 kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
Commentary on Twitter
Thrilled to see our publication out today in @JAMANeuro using #SCS to treat #diabetic #pain. 86% of patients with over 50% pain relief at 6 months with better sleep and walking! #progress #needherscience #neuromodulation @UAMSneurosurg @UAMSPain @uamshealth https://t.co/TJQPHsHvSa
— Dr. Erika Petersen (@ErikaPetersenMD) April 5, 2021
Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?
9 Apr, 2021 | 03:28h | UTC
Chronic Coronary Syndromes in Women: Challenges in Diagnosis and Management
6 Apr, 2021 | 01:08h | UTC
RCT: Effect of intravitreous anti–vascular endothelial growth factor vs. sham treatment for prevention of vision-threatening complications of diabetic retinopathy
6 Apr, 2021 | 01:02h | UTCCommentaries: Preventive treatment reduces diabetic retinopathy complications – NIH News Releases AND Prevention of Severe Nonproliferative Diabetic Retinopathy Progression With More at Stake Than Visual Acuity – JAMA Ophthalmology AND Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression – JAMA Ophthalmology
Author interview: Randomized Trial of Anti-VEGF to Prevent Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME) – JAMA
Commentary on Twitter
In this study, aflibercept injections reduced the development of vision-threating complications; however, through 2 years, preventive treatment did not confer visual acuity benefit compared with observation plus aflibercept if complications developed https://t.co/q4ABSKOMVj
— JAMA Ophthalmology (@JAMAOphth) March 30, 2021
Integrating Transwomen and Female Athletes with Differences of Sex Development (DSD) into Elite Competition: The FIMS 2021 Consensus Statement
28 Mar, 2021 | 22:06h | UTC
RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity
24 Mar, 2021 | 08:05h | UTCEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial – JAMA (free for a limited period)
Commentaries: Continuing Semaglutide Leads to Further Weight Loss – NEJM Journal Watch AND STEP 4: Long-term treatment needed for full semaglutide benefit – MedwireNews
Podcast: Semaglutide for Weight Loss – JAMA
Commentary on Twitter
In this RCT, weekly subcutaneous subcutaneous semaglutide resulted in increased weight loss over 48 weeks vs placebo in adults with #overweight or #obesity https://t.co/Ze6zHCG1Fd
— JAMA (@JAMA_current) March 23, 2021
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study
24 Mar, 2021 | 08:02h | UTCCommentaries: Eating More Ultraprocessed ‘Junk’ Food Linked to Higher CVD Risk – TCTMD AND Ultra-Processed Foods and Incident Cardiovascular Disease – American College of Cardiology